{'fraction_non_alphanumeric': 0.024582967515364356, 'fraction_numerical': 0.004389815627743635, 'mean_word_length': 5.333333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cardiac metastasis of a uterine leiomyosarcoma

Uterine leiomyosarcoma (ULMS) is a rare malignancy of the myometrial smooth muscle that accounts for 1%–2% of cancers arising in women of postmenopausal age. ULMS is associated with significant morbidity and mortality, largely due to its ability to metastasize. The most common sites of metastasis include the lungs, bone, and liver. However, in rare cases, ULMS can metastasize to the heart and should be considered in patients with concomitant cardiovascular symptoms and known history of ULMS or risk factors of ULMS. Here, we report a case of a 74-year-old female who was diagnosed with ULMS-derived cardiac metastasis. Currently available treatment plans for cardiac metastasis involve a combination of medications such as mesna, doxorubicin, ifosfamide, and dacarbazine; radiation to the cardiac muscle; and resection of the mass. Given the significant improvement in the 5-year survival rate of patients who are promptly and accurately diagnosed, physicians should consider the possibility of cardiac metastases when patients with a history of ULMS present with cardiac abnormalities.